It is well known that ticarcillin (TIPC) has a very broad antibacterial spectrum1,2). However, TIPC is somewhat susceptible to hydrolysis by the (3-lactamases produced by certain Gram-negative bacteria, resulting in loss of antibacterial activity3). Since clavulanic acid (CVA) irreversibly inhibits the (3-lactamases belonging to Richmond types II, III, IV and V4), a combined formulation of amoxicillin (2 parts) and CVA (1 part) (Augmentin) has been developed for oral use5,6) and shown to be extremely effective against many infections caused by i9-lactamase-producing bacteria.
BRL28500 is a new formulation of TIPC (15 parts) with CVA (1 part), developed for parenteral use7-9) which has already shown some promise in the clinic10). In this report, we report the results of both in vivo and in vitro studies of the activity of BRL28500 against (3-lactamase-producing strains of Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus. Materials and Methods
Antibiotics and Test Strains
Ticarcillin sodium salt (TIPC), BRL28500 (a formulation of 15 parts TIPC and 1 part CVA) and clavulanic acid potassium salt (CVA) were provided by Beecham Yakuhin K.K., Tokyo, Japan. The bacterial strains used were clinically isolated in Japan. THE 
JOURNAL OF ANTIBIOTICS
Determination of MICs MICs were determined by the standard serial 2-fold dilution method, using heart infusion agar (Nissui Pharmaceutical Co., Ltd., Tokyo). An overnight culture (about 108 cells per ml) in Trypticase soy broth (Nissui) was used for inocula. After incubation at 37°C for 18 hours, the MICs were defined as the minimum drug concentration which completely inhibited the growth of bacteria.
Preparation of Crude ~-Lactamases An overnight culture was inoculated into Trypticase soy broth to a final concentration of 5 %. The cultures were incubated for 4 hours at 37°C with shaking, harvested by centrifugation, washed twice with 0.1 M phosphate buffer (pH 7.0) then resuspended in the same buffer. The bacteria were disrupted by sonicator (Heat Systems-Ultrasonic, Inc., Plainview, N.Y.) in an ice bath at 20 kHz for 10 minutes. Crude (3-lactamase was prepared by ultracentrifugation (100,000 x g) for 40 minutes at 4°C.
Assay of j3-Lactamase ji-Lactamase activity was determined by a modification of the NovlcK micro-iodometric method") using TIPC as substrate. Inhibition of ~-lactamase hydrolysis of TIPC was measured by incubation in 0.05 M phosphate buffer (pH 7.0) containing both TIPC and CVA and the 50 % inhibition (I50) value was obtained. The kinetic parameters were estimated by the least-squares method according to LINEWEAVER-BURK Plots. Protein content was determined by the method of LOWRY et al.12) using bovine serum albumin as the standard.
Lytic Activity and Residual Antibiotic Concentration Change of optical density (OD) at 600 nm was measured in heart infusion broth at the logarithmic growth phase using a Shimadzu 189 spectrophotometer.
At each sampling time, an equal volume of EtOH was added to the bacterial solution and after centrifugation, the concentration of antibiotics in the supernatant were determined by bioassay as described.
Observation of Morphological Changes A small amount of bacterial cells at the logarithmic growth phase was dropped onto a heart infusion agar film containing antibiotic on a glass slide. A cover glass was placed on the agar film and sealed with paraffin. Morphological changes of the cells at 37°C were observed by differential interference microscopy. Intraperitoneal Infections and Penetration of Antibiotics ddY Male mice, weighing 18 -20 g were inoculated by the intraperitoneal route with 0.5 ml of bacterial suspension in swine gastric mucin (Wako Co., Ltd., Tokyo) solution (pH 7.0). The inoculum was adjusted to 10 x to 50 x lethal doses by diluting the overnight culture of the test organism. Two hours after inoculation, mice were given subcutaneously 0.2 ml of antibiotic dissolved in saline. A group of ten mice was used for each dosage. The number of animals surviving after 7 days was recorded and the dose of antibiotic required to protect 50% of the infected animals (ED50) was calculated using the method of LITCHFIELD-WILCOXON13).
The concentrations of TIPC and CVA in peritoneal fluid of mice infected were also determined in the same manner as previously described"". At a predetermined time, the body fluids were taken from the peritoneal cavity and mixed with an equal volume of MeOH for sterilization. The supernatant was used for determination of the antibiotics by bioassay.
Bioassay
The concentration of TIPC was measured by paper-disc assay using Pseudomonas aeruginosa NCTC 10490 as the test organism. To determine CVA, a (3-lactamase inhibition assay using heart infusion agar plates containing 60 µg/ml of benzylpenicillin and 3 % of an overnight culture of K. pneumoniae NCTC 29665 producing penicillinase, was used. Table 1 shows the (3-lactamase activities against TIPC of the test organisms used. The table also shows the MICs of BRL28500 and its separate components, TIPC and CVA, against the organisms. The (3-lactamase activity of E. coil 113 was similar to that of E. coli 33, similarly the activities of K. pneumoniae 102 and K. pneumoniae 200 were similar. The production of 8-lactamase was highest for the S. aureus strain followed by E. coil and K. pneumoniae.
MICs of TIPC alone against the above five strains ranged from 2001tg/ml to over than 800 pg/ml, and the strains could thus be regarded as TIPC-resistant. However, there was no apparent correlation between the ~-lactamase activity and MICs of TIPC among the test organisms. In each case BRL28500
was substantially more effective than TIPC against /3-lactamase-producing strains of E. coli, K.
pneumoniae and S. aureus. Little or no advantage of BRL28500 over CVA was noted.
Lytic Activity
The time courses of changes in the optical density of culture solutions of E. coil 33 treated with At 400 pg/ml of TIPC the growth of cells was similar to that of the drug-free control. Addition of CVA at 50 µg/ml (MIC) to the cells showed inhibition of growth. BRL28500 at 50,ug/ml (MIC, equivalent to 47 pg/ml TIPC and 3 pg/ml CVA) showed strong lytic activity, particularly when compared with TIPC alone. This effect was further enhanced when BRL28500 was used at 100 µg/ml. Fig. 2 shows the lytic activity of BRL28500, TIPC and CVA against K. pneumoniae 200 when the cells were treated in the same manner as above. TIPC at a concentration of 200 µg/ml did not suppress growth. Cells treated with 50,ug/ml (MIC) of CVA lyzed 4 hours after addition. In contrast, marked lytic activity of BRL28500 was observed at a concentration of 25 pg/ml (1/2 MIC, equivalent to 23.5,ug/ml TIPC and 1.5,ug/ml CVA) at 1 hour after addition. Time after treatment (hours)
11.75,ug/ml TIPC and 0.75 pg/ml CVA) showed marked lytic action throughout the time of observation. The BRL28500 clearly showed stronger lytic activity against the test strains of E. coli, K.
pneumoniae and S. aureus than either CVA or TIPC alone.
Residual Activity in Liquid Cultures
The residual concentrations in bacterial cultures treated with 13111,28500, TIPC and CVA were measured simultaneously with the lytic activities.
TIPC at an initial concentrations of 50 yg/ml in the culture of E. coli 33 was decomposed completely 4 hours after addition, as shown in Fig. 4 (a) while CVA was stable under similar conditions. In contrast, when BRL 28500 was tested about 62 % of the TIPC was protected from hydrolysis for 6 hours. TIPC at an initial concentration of 50,ug/ml decomposed slowly. CVA and TIPC added as BRL28500
were not affected 6 hours after inoculation. Fig. 4(c) shows the P-lactamase activity of S. aureus L-5, which hydrolyzed 25 pg/ml of TIPC almost completely within 1 hour. In contrast, TIPC in BRL28500 was hydrolyzed only weakly.
CVA was stable in the culture of S. aureus L-5. • TIPC after addition of BRL28500, 0 CVA after addition of BRL28500, • TIPC after addition of TIPC. Time after incubation (hours) c
Morphological Changes Fig. 5 shows a micrograph of E. coli 33 exposed to various concentrations of BRL28500, TIPC and CVA for 3 hours on an agar film. No morphological change was observed in the bacterial cells exposed to 400 pg/ml of TIPC (Fig. 5B) , when compared to the control (Fig. 5D ). The cells exposed to more than 25 pg/ml (1/2 MIC) of CVA assumed a round formation attended by "rabbit ears" (Fig.  5C ). In contrast, the cells exposed to BRL28500 at the MIC (50 pg/ml, equivalent to 47 icg/mI TIPC and 3 pg/ml CVA) became filamentous, and several spherical and lyzed cells were observed (Fig. 5A ).
When the cells were exposed at half the MIC (25 pg/ml) rod shaped cells appeared but filamentous cells did not.
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Morphological changes in cells of K. pneumoniae 200 treated with the test compounds were similar to those in E. coli 33. The morphology of untreated cells is shown in Fig. 5H . When the cells were exposed to 1001tg/ml of TIPC, filamentous and spherical cells were formed gradually as shown in Fig. 5F . At less than 100pg/ml of TIPC, filamentous forms were more dominant. Cells exposed to the MIC (25 i'g/ml) or 1/2 MIC of CVA became spindle-shaped, similar to the changes observed in E. coli exposed to CVA alone. At 6.25 pg/ml (1/4 MIC), the cells assumed a round shape (Fig. 5G ).
When treated with concentrations of BRL28500 ranging from the MIC (50 leg/ml) to 1/16 MIC (3.13 jig/ml) filamentous cells were dominant and spherical cells appeared only occasionally (Fig. 5E) . Table 2 shows the therapeutic effects of BRL28500, TIPC and CVA against E. coli, K. pneunioniae and S. aureus infections in mice.
All untreated mice died within 24 hours of infection. Beneficial therapeutic effects of BRL28500
were observed with 3 test strains at doses of 2 -10 mg/mouse, against which TIPC or CVA alone was not effective under the experimental conditions. In particular, the greatest chemotherapeutic effect of BRL28500 was seen against K. pneumoniae 102. The in vivo efficacy against K. pneumoniae 200 could not be demonstrated because this strain is non-virulent in mice. Mice were treated with antibiotic subcutaneously 2 hours after intraperitoneal infection by bacteria. * 95 % confidence limit . As shown in Fig. 6 (a) the maximum peritoneal level for both BRL28500 and TIPC in mice infected with E. coli 113 occurred 15 minutes after dosing and decreased gradually thereafter. The peak level of TIPC achieved in the peritoneal cavity of mice treated with BRL28500 was higher than in mice treated with TIPC alone. Furthermore, the TIPC levels following dosing of BRL28500 were sustained longer than with TIPC alone. The elimination profile of CVA from the mice treated with BRL28500 was similar to the TIPC profile.
In the case of mice treated with K. pneumoniae 102 (Fig. 6b) , the maximum peak level of TIPC achieved in the peritoneal fluids of mice receiving BRL28500 occurred at 60 minutes after dosing but in the mice dosed with TIPC alone the peak level was detected at 30 minutes.
Thus the maximum peritoneal half-life of TIPC dosed as BRL28500 was higher and longer than when TIPC was administered alone.
The maximum concentration of CVA dosed as BRL28500 was achieved after 60 minutes and coincided with the peak level of TIPC from BRL28500.
When the mice infected with S. aureus L-5 were treated with BRL28500 (Fig. 6c) , peak levels of TIPC and CVA were observed after 30 minutes. Both compounds were still detectable 3 hours after dosing.
In contrast in mice treated with TIPC alone the level fell rapidly from the peak reaching the minimum in 1 hour.
(3-Lactamase Inhibitory Activity of Clavulanic Acid Kinetic studies of (3-lactamase inhibition by CVA are shown in Fig. 7 . The affinity of CVA to S. aureus L-5 /3-lactamase was found to be higher than that to the other (3-Iactamases and the inhibitory action of CVA was found to be irreversible. The TIPC concentration was 0.2 mm as substrate. TIPC and CVA were incubated simultaneously for 30 minutes at 30°C.
Discussion
It has been previously reported that the binding of TIPC to penicillin binding protein 3 (PBP 3) in E. coli causes the formation of filamentous cells".
On the other hand CVA causes the formation of round cells, due to specific binding to PBP 216). Generally speaking, a combination of P-lactam antibiotics having affinity for different PBPs exerts a synergistic effect. The lytic effect of BRL28500 was more pronounced than that of TIPC or CVA alone, indicating synergism of these j3-lactams. The morphological changes of E. coli 33 and K. pneumoniae 200 cells treated with BRL28500 at the MIC level were similar to those observed by treatment with TIPC alone, i.e. they became filamentous and, in part, spherical. Formation of round cells, typically induced by CVA, was observed only to a small extent in cells treated with BRL28500. Thus, synergistic morphological change was not markedly evidenced in BRL28500. A more detailed morphological study using electron microscopy may be needed to explain the enhanced antibacterial activity of BRL28500.
It has been reported that CVA irreversibly inhibits plasmid-mediated ~-lactamase produced by Enterobacteriaceae, Haemophilus influenzae, S. aureus, Neisseria gonorrheae, Branhamella catarrhalis, and chromosomally-mediated 8-lactamases produced by Proteus vulgaris, K. pneumoniae and Bacteroides fragilis6, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, inhibition of the cephalosporinases produced by Gram-negative bacilli is rather weak4). Consistent witll these reports, Ki and 150 values of CVA against the S. aureus L-5 46-lactamase, which is plasmid-mediated, were lowest among the 5 strains used in this experiment. I50 values of CVA against type III P-lactamase of E. coli 33 and E. coli 113, and type IV ~-lactamase of K. pneumoniae 102 and K. pneumoniae 200 were moderate and similar to each other, indicative of their similar enzymatic nature. The ~-lactamase inhibiting activity of CVA in BRL28500 was well demonstrated by MIC value, lytic activity, ED,, value and residual drug levels as compared with TIPC alone. It is noted that the addition of CVA to TIPC in a ratio of 1: 15 was sufficient to suppress the &-lactamase activity of the tested strains.
Since BRL28500 is a combinatin of TIPC and CVA, it is important that the components show similar pharmacokinetic behavior in vivo in order to obtain maximum synergy. It has been reported earlier that TIPC and CVA are well distributed throughout the human body with similar pharmacokinetic parameters following administration of BRL2850021). Furthermore, the present work shows that, after administration to infected mice, TIPC and CVA are similarly distributed. The higher concentration and longer duration of TIPC in the peritoneal cavity of the infected mouse following administration of BRL28500 than those of achieved after administration of TIPC alone indicate that CVA of BRL28500 actually protected TIPC from hydrolytic inactivation by the /3-lactamases of the tested strains. These observations explain the greater efficacy of BRL28500 for mice infected with TIPC-resistant strains when compared to that of TIPC or CVA alone. 
